TAT 2016: Targeted anticancer therapies
19 Jun 2015
TAT 2016: Targeted anticancer therapies
Comment: Venetoclax with rituxumab highly active in relapsed refractory CLL
EHA 2015 highlights
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma
Biomarkers for childhood relapsed acute lymphoblastic leukaemia
Are CML patients being treated to the correct standard?
Exciting new developments in proton therapy treatments
PDL1 expression in thymic tumours
Exciting update on the Repurposing Drugs in Oncology (ReDO) project
EHA 2015: Reviewing the treatment landscapes of CLL, MCL, and MM
Overview of innovation in Hodgkin's lymphoma
Applications of chimaeric antigen receptor T-cells in leukaemia